Ten-million-person study links semaglutide to lower COVID-19 mortality
After accounting for major health differences between semaglutide users and non-users, researchers identified a striking mortality association that…
Newer GLP-1 medications may reduce alcohol-related hospitalization risk
Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes by people with alcohol-use disorder…
Physical activity declines after starting GLP-1 obesity treatments
Adults with obesity losing weight with glucagon-like peptide-1 (GLP-1) receptor agonist medications significantly decreased their physical activity, which…
Investigating microglia’s role in Alzheimer’s pathology
Announcing a new article publication for BIO Integration journal. Alzheimer’s disease (AD) is a neurodegenerative disorder and the…
Short-duration psychedelic therapy shows promise for major depression treatment
A controlled clinical trial suggests a fast-acting psychedelic approach may reduce depressive symptoms, but researchers stress careful interpretation…
Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers
A deep dive into public Facebook posts uncovers the real-world side effect patterns of GLP-1 medications, revealing what…